What do systematic reviews say?

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 608 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with TKI (peptide‐Fc fusion protein) vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 315 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1340 participants
  Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 486 participants
  Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 890 participants
  High

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 744 participants
  Moderate

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

• Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 53 participants
  Very low

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs chemotherapy alone

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 229 participants
  Low

Chemmotherapy combined with biological therapy vs chemotherapy alone

Chemmotherapy combined with biological therapy showed no clear difference in quality of life (QoL) compared with chemotherapy (low certainty).

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  HR 0.88 [0.74, 1.04]
  2 studies · 1154 participants
  Low

Non‐platinum therapies vs platinum combination

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 5 participants
  GRADE not reported

Non‐platinum single‐agent vs non‐platinum combination treatment

• Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2 participants
  GRADE not reported

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

• Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 339 participants
  Moderate